

Published: November 30, 2022

**Citation:** George Georgiou, 2022. Eradication of *Borrelia Burgdoferi in vitro* using Chlorine Dioxide: A Novel Approach, Medical Research Archives, [online] 10(11).  
<https://doi.org/10.18103/mra.v10i11.3279>

Copyright: © 2022 European Society of Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI

<https://doi.org/10.18103/mra.v10i11.3279>

ISSN: 2375-1924

## RESEARCH ARTICLE

### Eradication of *Borrelia Burgdoferi in vitro* using Chlorine Dioxide: A Novel Approach

**George Georgiou**

\*[admin@worldwidehealthcenter.net](mailto:admin@worldwidehealthcenter.net)

#### ABSTRACT

Lyme disease, which is caused by the spirochete *Borrelia burgdorferi* is the most prevalent tick-borne illness in the world today and has grown into a major public health problem during the last decade, irrelevant to decades of efforts from various health professionals.

The conventional treatment for Lyme disease is the use of a variety of antibiotics, but relapse often occurs when antibiotics are discontinued. There are several reasons why this relapse may occur, given that *B. burgdorferi* is a pleomorphic microorganism that can convert from vegetative spirochetes to a variety of different round bodies and biofilm colonies. Therefore, there is an urgent need for novel approaches that can eliminate all these different morphologies.

This has challenged many health practitioners around the world, not to mention the suffering of many afflicted people. In this study, Chlorine dioxide (CD) at different concentrations was tested for its effectiveness *in vitro* against *B. burgdorferi* using combined fluorescent and darkfield microscopy with Live-or-Dye staining methods. Our experiments demonstrated that it is possible to completely eradicate all forms of *B. burgdorferi* at specific concentrations of Chlorine dioxide. Our extensive research has shown that Chlorine dioxide can be used for the eradication of *B. burgdorferi* morphologies.

At certain concentrations of chlorine dioxide above 2 ppm the *Borrelia* morphologies appear to be eradicated as there is no motility of either spirochetes or round bodies, only biofilms visible. However, incubating again for another 7 days resulted in the *Borrelia* being motile again as they come out of the biofilms.

We, therefore, decided to conduct each experiment with what we termed the Regrowth Kill Test (RKT) by incubating the initial sample with the CD in an incubator at 37 degrees centigrade in the Campypack for 7-days. It appeared that the biofilms that are quickly formed as soon as the CD is added in the initial experiment, broke up and released small spirochetes and round bodies of different morphologies.

After numerous RKT experiments, it was determined that the concentration that resulted in a near complete disinfection of the spirochetes as well as round bodies was 30 ppm CD.

## Introduction

Lyme disease (LD), also known as Lyme borreliosis, is caused by the different genospecies of the spirochaete bacterium *Borrelia burgdorferi* sensu lato group<sup>1-3</sup> and is the most reported tick-borne infection in Europe and North America, which is also endemic in many areas in Asia<sup>3,4</sup>

*Borrelia* consist of thin, spiral-shaped motile bacteria, with 7 to 11 flagellae in the periplasmic space, enveloped around the cell and attached to the poles. The genetic structure of *Borrelia burgdorferi* is quite unusual and the entire genome has been mapped and consists of a 950 Kbp linear chromosome and an additional 500,000 base pairs spread over 9 small linear and 12 circular plasmids.<sup>88</sup>

According to insurance claims data from 2010 – 2018, the CDC recently estimated ~476,000 diagnosed cases of LD every year in the USA.<sup>5</sup> As the most prevalent vector-borne disease in the Northern Hemisphere<sup>6,7</sup>, it is now considered an escalating health threat that is costing well over \$1 billion per year in the USA alone.<sup>8</sup>

The general medical treatment for LD is the use of a cocktail of antibiotics for a 2–4-week period or longer. However, studies have shown that 36-63% of patients treated with these antibiotics still suffer from persistent symptoms,<sup>9</sup> a condition that has been termed Post Treatment Lyme Disease (PTLD), characterized by infection-induced immune dysfunction or auto-immunity, chronic inflammation, persistent bacterial infections, neurological symptoms, and other tick-borne symptoms.

The purpose of this in vitro research is to find the correct dosage of a natural antimicrobial, chlorine dioxide, that can eradicate *Borrelia* and its pleomorphic morphologies and biofilms.

## Post Treatment Lyme Disease (PTLD)

PTLD patients are generally treated with more antibiotics over a prolonged period, but this approach may be both dangerous<sup>10,11</sup> and ineffective.<sup>12,13,14,15</sup> The general conclusion from these studies was that additional antibiotics for PTLD did not benefit patients compared to a placebo group.

## Pleomorphic Characteristics of *Borrelia*

The question of what causes PTLD is a long-standing one. One feasible explanation has to do with the fact that *B. burgdorferi* sensu lato is pleomorphic<sup>16,17,18</sup> as it can change its morphology from spirochaetes to round bodies that consist of cell wall deficient (CWD) forms, L-forms, or spheroplasts.<sup>19,20</sup>

Changes in the internal milieu with prolonged antibiotic use<sup>21</sup> can interfere with the cell wall synthesis leading to a considerable loss of peptidoglycan cell wall, leading to the morphological changes mentioned here. Additionally, various bacteria can also aggregate into biofilms.<sup>22,23,24,25</sup>

The in vitro pleomorphic or polymorphic characteristics of *B. burgdorferi* have been identified in several studies,<sup>26,27,28,29,30,31</sup> as well as in clinical samples.<sup>22,32,33</sup>

The flat-wave forms of *B. burgdorferi* spirochetes are the most common, but there are many other morphologies such as blebs, round bodies (RB) and cell wall deficient forms, looped or ring-shaped forms, and spirochete colonies or biofilm aggregates.<sup>57, 58-72</sup>

Hostile environments such as pH, temperature, oxidative stress, change of media composition, acidity/alkalinity, concentrations of salts, sugars, or other organic compounds or antibiotic treatments can all change the morphology from spirochetes to RB such as granules, cysts, spheroplasts or vesicles.<sup>73-81</sup>

Many researchers have mistaken the transformation of the motile forms into a RB as a decrease in pathogen viability. However, even though RBs are less motile than spirochetes, they are still able to revert to the active growing reproductive spirochetes when the conditions are favourable.<sup>64, 70-73,74-76,80,82</sup>

Antibiotic treatment of *B. burgdorferi* results in biphasic killing<sup>83-84</sup> – certain bacteria are eliminated but concomitantly another group of drug-tolerant cells appears known as persisters.<sup>85-86</sup> As the concentration of antibiotics reaches a certain threshold, only persister cells survive.<sup>87</sup> Persisters have not been genetically modified to develop resistance, they are simply tolerant to the antibiotics in a non-inheritable way.<sup>88</sup> Persisters can also transform to “reverters” (replicating forms) under the right conditions, and will therefore cause further relapses and chronic infection.<sup>84-87</sup>

Given the protective mechanisms involved in the pleomorphic abilities of *B. burgdorferi*,<sup>34,35,36,37</sup> this in vitro research is oriented to finding effective natural substances that can eradicate all pleomorphic forms, including the persisters and reverters.

## Chlorine Dioxide (ClO<sub>2</sub>)

This research chose Chlorine dioxide (ClO<sub>2</sub>) for a variety of reasons. ClO<sub>2</sub> is a small molecule (0.214 nm) with a molecular weight of 67.46, and it forms a stable radical.<sup>89</sup> It is smaller than the

smallest virus, so can penetrate all areas of the body including the blood brain barrier.

$\text{ClO}_2$  is an oxidizer, which is reduced to chlorite ion ( $\text{ClO}_2^-$ ) by capturing an electron ( $\text{ClO}_2 + e^- \rightarrow \text{ClO}_2^-$ ). It does no harm to the human microbiome.<sup>90,91</sup> as the redox potential ( $E^\circ$ ) is relatively high at 0.95V.

Another reason to choose  $\text{ClO}_2$  was its ability to remove biofilms swiftly because it is highly soluble in water and can penetrate biofilms rapidly to reach and kill the microbes living within the film.<sup>39</sup>

Most research on *Borrelia* species has been focused mainly on antibiotic efficacy, the different pleomorphic forms of the organism, survival in multiple host types based on protein regulation, and persistent infections.<sup>49</sup> However, very little research has been published on *Borrelia*'s susceptibility to disinfection using natural products such as chlorine dioxide.

Chlorine dioxide is bactericidal, viricidal, sporicidal, cysticidal, algicidal, and fungicidal.<sup>92</sup>

Several researchers in different research studies have shown that chlorine dioxide is a strong oxidant that can greatly inhibit and eradicate microorganisms at different concentrations ranging from 1 to 100 ppm. Indeed, it was shown that chlorine dioxide has potent antiviral activity, inactivating 99.99% of viruses upon a 15-second exposure.<sup>92-96</sup>

One of the remarkable properties of chlorine dioxide that has not been achieved by either allopathic or natural medicine, is the breakdown of protective biofilms, due to their hydrophilic properties. Unlike ozone, chlorine dioxide does not react with the extracellular polysaccharides of the biofilm, therefore it is capable of penetrating biofilms rapidly to reach and kill the microbes living within the film.

There are many reports that  $\text{ClO}_2$  has virucidal activity.<sup>98-102</sup> The inactivation concentration against various viruses is 1-2 ppm in poliovirus,<sup>98,99</sup> 2.19 ppm in coronavirus which causes SARS,<sup>100</sup> 7.5 ppm in hepatitis A virus,<sup>101</sup> and 0.2 ppm in rotavirus.<sup>102</sup>

### Safety of Chlorine Dioxide

Chlorine dioxide has been used for over 50 years and has been shown to be non-toxic and safe, with no adverse effects on health.

Chlorine dioxide has been used in areas such as water treatment, textile industries, bleaching of pulp and paper, and the elimination of unwanted tastes and odours.

Various toxicological tests have been tried over decades, such as drinking chlorine dioxide dissolved in water, injecting it directly into the blood and under the skin of animals and into the brains of mice, adding it to tissue cultures, as well as using it with burns, disinfecting seeds and insect eggs and injecting into the stalks of plants.<sup>103,104</sup>

One study with human volunteers had shown that drinking chlorine dioxide up to 24 ppm in water, demonstrated no adverse effects.<sup>105</sup>

Moreover, there was no evidence found of foetal malformations or birth defects with chlorine dioxide concentrations of up to 100 ppm in reproductive toxicology and teratology.<sup>106-108</sup>

Further studies with rats fed up to 1,000 mg/l for 6 consecutive months did not show any significant haematological effects. Feeding the rats for 9 consecutive months resulted in a decrease in red blood cell counts, haematocrit, and haemoglobin.

In other toxicity studies, rats<sup>109</sup> and honeybees<sup>110</sup> were fed chlorine dioxide in high doses of up to 100 ppm for two years, without showing any adverse effects.

## Methodology

### Materials and Methods

#### Types of Chlorine dioxide Used in Testing

The Chlorine dioxide ( $\text{ClO}_2$ ) used in these experiments came in three different forms: CDSplus®<sup>38</sup> which is a patented, pure, buffered solution of chlorine dioxide solution (approx. 2.9g/l = 0.29%/l = 2,900 ppm) at a pH of 7. The other form was CDSPure® which is a chlorine dioxide solution in a sealed glass ampoule that has been nano-filtered and is pH neutral and chlorine free.<sup>38</sup> The third type is CDS which is a pure chlorine dioxide gas bubbled into distilled water.

*Borrelia burgdorferi* bacteria were obtained from ATCC, Germany<sup>50</sup> in a frozen vial, with strain designation B31, which was thawed at room temperature, and aseptically transferred to a 10ml tube of fresh Barbour-Stonner-Kelly (BSK-H) growth media with 6% rabbit serum. One-tenth of this cell suspension was transferred to 2 additional 10ml tubes of fresh growth media. The remaining contents were transferred in cryovials and stored in liquid nitrogen.

The *Borrelia* was cultured in a specialized media Barbour-Stonner-Kelly (BSK-H) medium that is highly enriched with bovine serum albumin and contains 6% heat-inactivated rabbit serum which is critical for proper growth.<sup>52</sup>

The culture was incubated in a microaerophilic environment using a Campyack

placed in an ordinary incubator at the optimal temperature of 37° C.<sup>52</sup> Generally, spirochetes grow slowly and *Borrelia burgdorferi* doubles every 12 hours approximately in the correct anaerobic conditions provided by the Campypack as opposed to a 5% CO<sub>2</sub> incubator.

Specimens of *Borrelia burgdorferi* cultures or cells were examined on a slide with a coverslip using a Zeiss Axioplan 2 Imaging microscope equipped with a Zeiss darkfield Ultra condenser 1.2/1.4 (0.75-1.0) and a Zeiss darkfield oil immersion 40X objective lens. The microscope is also equipped with fluorescence capabilities, as well as a Zeiss Axiocam MRc5 colour camera.

The *Borrelia* spirochaete is thin and difficult to view using brightfield or phase contrast. Darkfield microscopy will allow the different morphologies to appear as bright objects surrounded by a dark background as they are stained by light, and the contrast allows for simple spirochete identification.<sup>51</sup>

In these experiments, fluorescence microscopy with darkfield was used simultaneously (Diascopy) as the darkfield condenser directs the excitation light with a strong inclination towards the sample, so very little light enters the objective. The image is intensely fluorescent on a dark background as all light is blocked by the spread of the excitation barrier filter.<sup>56</sup>

### Live/Dead Differentiation of Lyme Spirochetes

*Borrelia* spirochetes cannot be counted on automatic microbial counters due to their size and pleomorphic characteristics. We, therefore, needed to devise a method to differentiate live from dead *Borrelia* forms and count them under the microscope.

To differentiate live and dead *Borrelia* forms and obtain the percent of live/dead cell measures, darkfield microscopy was used, along with fluorescent microscopy using a FITC filter cube (blue) and the Live-or-Dye™ Fixable Viability Staining Kits (488/515) from Biotium<sup>53</sup> which is designed for discrimination between live and dead cells during flow cytometry or microscopy.

Live-or-Dye™ Fixable Viability Stains are cell membrane impermeant amine-reactive dyes. The dyes can enter dead cells that have compromised membrane integrity and covalently label-free amines on intracellular proteins, so only the dead cells will fluoresce a bright, light-blue colour, with the live cells being far dimmer.<sup>54</sup>

Samples were prepared from the cryovials by adding 1µl of Live-or-Dye™ Fixable Viability Stain and adding it to 100µl of culturing broth (BSK-medium ready to use), to prepare the working

stock of the day. From each working stock, 20µl were then added to 100µl of *Borrelia* culture, to produce the experimental tube, followed by incubation at room temperature for 30 minutes.

Once the incubation was complete, the Chlorine Dioxide (CD) solution was added to the experimental tube, depending on the number of experiments to be run on that day. Different CD concentrations were used depending on the experiment being conducted.

Immediately after CD was added to the experimental tube, a sample was taken and placed onto a slide with a coverslip and observed under darkfield/fluorescence microscopy (Diascopy). The motility of the spirochaetes and round bodies was observed, and the percentage live/dead was estimated based on the fluorescence resulting from the Live-or-Dye™ Fixable Viability Stain.

### The Regrowth Kill Test (RKT)

Preliminary experiments had found that the CD acts on the *Borrelia* immediately, making all the morphological forms immotile within seconds, so measuring contact times was superfluous.

However, if the immotile sample was left for a day or so in the incubator, and re-examined on the microscope, the small round bodies would regain their motility again.

It was therefore decided to add what we termed the Regrowth Kill Test, testing the sample with the added CD again 7-days after the initial viewing.

So, after exposure to the CD, the *Borrelia* cells were washed, and new BSK-H media added (500 ul) and placed back in the Campypack jar in a normal incubator at 37°C for a further 7-days to determine whether there was any further regrowth detectable over time.

One-week post-inoculation with the CD, the cells were again removed and re-examined under the darkfield microscope using the FITC fluorescent filter for spirochaete mobility. These experiments were run in triplicate and the average was taken.

The *Borrelia* was observed for motility of spirochetes and round bodies, as well as the fluorescence of the dead cells. Estimated counts were made of each for each concentration of CD used.

The ASTM E2315-16 standard test method was adapted and used in this study for assessing bactericidal activity in liquid suspension.<sup>55</sup> In addition, live/dead viability assessment of the samples via Biotium's fluorescent viability dye named Live-or-Dye™ viability stain. All disinfection efficacy tests were conducted in triplicate.

## Results

### Assessing Antimicrobial Sensitivity

To evaluate in vitro chemical antimicrobial sensitivity of *B. burgdorferi* spirochete and round body morphological forms, *B. burgdorferi* (B31-35210) was subjected to contact with the CD at different concentrations from 1 - 30 ppm, in 5 ppm intervals.

Mobility and viability of spirochetes and round bodies were evaluated using direct cell counting of live and dead cells – dead cells fluoresce a bright-blue colour using the FITC cube (excitation 450-490nm) – as well as motility assessment using darkfield microscopy.

All experiments were conducted in triplicate and compared with a control sample without disinfectant.

Microscopy images were taken, as well as video to determine the mobility of the *Borrelia* spirochaetes and round bodies.

Here are a few examples of the images obtained. The initial experiments found that any concentration of CD at 2 ppm or higher would result in the mobility of spirochaetes and round bodies being 0%, with large biofilms forming, whether this was viewed in darkfield or darkfield-fluorescence.

Figure 1A shows the control sample of *Borrelia* with no CD added – the image is teeming with live, motile spirochetes and round bodies of different morphologies. We have considered the control sample to have 100% motility.

Figure 1B is the same sample but seen under Fluorescent-Darkfield microscopy (Dioscopy) using an excitation wavelength of 450-490nm with the FITC cube. Only the dead bacteria will phosphoresce a bright, light-blue colour using the Live-or-Dye™ viability stain. In this case, as all the bacteria are alive, there is very little phosphorescence seen. We can refer to this as 0% phosphorescence, which is equivalent to 100% motility or live.




Figure 1A - Control under Darkfield (no CD)




Figure 1B - Control under Fluorescence (no CD)

Figure 2A shows a sample of *Borrelia* under darkfield disinfected with 3 ppm of CD. There are no motile spirochetes or round bodies, only medium to large-size biofilms. This indicates 0% motility.

Figure 2B is the same sample but seen under Fluorescent-Darkfield microscopy using the Live-or-Dye™ viability stain. There is 0% motility with no spirochetes visible and no motile round bodies, but only highly phosphorescent masses of biofilms.




Figure 2A - 3 ppm CD under Darkfield




Figure 2B - 3 ppm CD under Fluorescence

### Regrowth Kill Test (RKT) Results

In initial pilot experiments, we found that samples that had been disinfected with 2 ppm or higher and showed 0% motility, if they were placed back in the incubator in the Campypack for a few days, then the round bodies would come out of the biofilms and would be motile again. These initial pilot experiments were conducted using concentrations of CD from 1 – 5 ppm (Table 1, Graph 1).

We, therefore, decided to conduct each experiment with what we termed the Regrowth Kill Test (RKT) by incubating the initial sample with the


CD in an incubator at 37 degrees centigrade in the Campypack for 7-days. It appeared that the biofilms that are quickly formed as soon as the CD is added in the initial experiment, broke up and released small spirochetes and round bodies of different morphologies.

So, when 2 ppm of CD was initially added, biofilms were immediately formed and there was 0% motility detected. However, 7 days after incubating this sample, there was 60% motility observed under fluorescent-darkfield (Table 2, Graph 2). The same had occurred for concentrations of CD ranging from 2-5 ppm and above.

**Table 1** – Percentage motility with CD in Initial Experiment vs Regrowth Assay 7-Days Later

CD (PPM)	% MOTILITY – INITIAL EXP	% MOTILITY – REGROWTH KILL TEST
CONTROL	100%	100%
1 PPM	80%	80%
2 PPM	0%	60%
3 PPM	0%	60%
4 PPM	0%	60%
5 PPM	0%	60%

N.B. All experiments were performed in triplicate, and these are the averages




Further experiments increased the concentration of CD in 5 ppm increments, from 10 ppm up to 80 ppm. Table 2 shows that all concentrations used increased the motility of spirochetes and other round bodies in the RKT 7 days later (Table 2, Graph 2).

There is only one concentration of CD (30 ppm) that decreased the mobility to 2% during the RKT - these were only round bodies with no spirochetes of any size visible. This experiment was repeated in triplicate for all these concentrations and the results were the same as indicated in Table 2, Graph 2, and Figures 3A and 3B.

**Table 2 – Percentage motility with CD in Initial Experiment vs Regrowth Assay 7-Days Later**

CD (PPM)	% MOTILITY – INITIAL EXP	% MOTILITY – REGROWTH ASSAY
CONTROL	100%	100%
10 PPM	80%	60%
15 PPM	0%	65%
20 PPM	0%	50%
25 PPM	0%	20%
30 PPM	0%	2%
35 PPM	0%	40%
40 PPM	0%	50%
45 PPM	0%	50%
50 PPM	0%	50%
55 PPM	0%	50%
60 PPM	0%	50%
65 PPM	0%	40%
70 PPM	0%	40%
75 PPM	0%	30%
80 PPM	0%	30%

N.B. Averages of experiments performed in triplicate



Furthermore, all the above-mentioned experiments were repeated in triplicate using all three forms of chlorine dioxide (ClO<sub>2</sub>) used, namely, CDSplus®,<sup>38</sup> CDSPure®, and CDS which is a pure chlorine dioxide gas bubbled into distilled water.

The results were not affected by the different types of chlorine dioxide, if the concentrations were correct.

Figure 3A shows a *Borrelia* sample disinfected with 30 ppm CD under darkfield. There are no spirochetes or round bodies visible, only large-sized biofilms.

Figure 3B is the same sample but seen under fluorescence-darkfield microscopy with stain. There is 2% motility of small round bodies, with no spirochetes visible, and high phosphorescent masses of biofilms




Figure 3A- 30 ppm CD under Darkfield (RKT)




Figure 3B- 30 ppm CD under Fluorescence (RKT)

In the initial pilot experiments, small dosages of CD were tried to determine the effect on the motility of the various morphologies of *Borrelia*. It was found that 1 ppm CD still resulted in

over 80% motility. However, concentrations over 2 ppm or higher were found to result in 0% motility during the initial experiments (Table 1, Graph 1).

## Discussion

These experiments have brought some interesting results to light that hopefully will enrich the research literature and help clinicians treating Lyme Disease to make better clinical decisions.

It appears that chlorine dioxide is a powerful antimicrobial that can help to eradicate *Borrelia* morphologies in vitro. However, our experiments have shown that it appears to be dose-dependent and works best at concentrations of 30 ppm. The reason for this is not clear from this research.

In the initial experiments, even small dosages of 2 ppm or higher were seen to decrease the motility of the spirochetes and round bodies to 0%. However, if this sample was re-incubated for a further 7 days at 37 degrees centigrade (Regrowth Kill Test), then the biofilms would break up and release many motile round bodies with small spirochetes.

What we are observing in vitro is probably what is happening in the body, as health practitioners around the world are having difficulties eradicating *Borrelia* using either pharmaceutical or natural antimicrobials.

*Borrelia* is a pleomorphic<sup>16,17,18</sup> microorganism and this is probably the reason why 36-63% of patients treated with these antibiotics still suffer from persistent symptoms,<sup>9</sup> a condition that has been termed Post Treatment Lyme Disease (PTLD).

Internal changes such as pH, temperature, oxidative stress, change of media composition, acidity/alkalinity, concentrations of salts, sugars, or other organic compounds or antibiotic treatments can all change the morphology from spirochetes to RB such as granules, cysts, spheroplasts or vesicles.<sup>73-81</sup> Additionally, various bacteria can also aggregate into biofilms.<sup>22,23,24,25</sup>

This research confirms what many other scientists have mistaken as a decrease in pathogen viability when there is a transformation of the motile spirochaetes into RBs. We have shown here in vitro that motile RBs can transform into active growing reproductive spirochetes when the conditions are favourable.<sup>64,70-73,74-76,80,82</sup>

The dose-dependent results that we have obtained using CD with *Borrelia* may be a result of persisters.<sup>85-86</sup> When the concentration of antimicrobials exceeds a certain threshold, only persister cells survive.<sup>87</sup> It is possible for persisters to undergo a change to “reverters” (replicating

forms) under the right conditions, therefore causing relapse and chronic infection.<sup>84-87</sup>

Immersing the *Borrelia* morphologies in a 30 ppm concentration of CD seems in vitro to prevent the persisters from transforming to reverters. This was the only concentration that resulted in a near complete disinfection of the *Borrelia* morphologies (only 2% motile after the 7-days of the RKT).

There were many experiments performed using concentrations of CD from 1 – 80 ppm. Even though concentrations of 2 ppm or greater would apparently result in complete eradication as soon as the CD was added, when the sample was placed back in the incubator for 7 days, the *Borrelia* morphologies became motile again.

The near complete disinfection was obtained at 30 ppm of CD after the 7-day RKT. This resulted in about 98% eradication of all morphologies including the spirochetes and the round bodies.

## Conclusions

It is interesting to note that this research has found that 30 ppm Chlorine dioxide is the optimal level required in vitro to eliminate motility in the initial experiments as well as the Regrowth Kill Test seven days later.

It would certainly be interesting for other researchers and clinicians to try implementing a clinical trial using this dosage of CD with patients diagnosed with Lyme's Disease and *Borrelia burgdoferi* bacteria.

There are sealed, sterile ampoules of CD (CDSPure®) – 5ml ampoules containing 2,990 ppm CD that can be used directly IV, or alternatively by mouth using CDSplus® - 100 ml bottle containing 2,990 ppm.

Clinical trials would need to be completed to gain clinical experience in what works best, however, extrapolating from the in vitro research it would be reasonable to use the following dosages.

For the average 70 kg adult, it would require one ampoule (5 ml = 2,990 ppm) of the CDSPure® in a 500ml saline IV infusion (1:100 dilution). Alternatively, 20 ml of the CDSplus® in a 1 litre bottle of water drunk over a few hours. It is likely that this would need to be repeated a couple of times per week until the level of *Borrelia* is eradicated, without giving the opportunity to regrow.

Various clinicians treating Lyme's disease have postulated that the round bodies as well as the spirochaetes can penetrate muscles and organs and “hide” there, protected from any type of antimicrobial. The chlorine dioxide molecule, however, is so small at 0.124 nm, that it is smaller

than the smallest virus and can therefore penetrate through the blood-brain barrier and other tissues of the body.

It is the hope of this author that other clinicians and researchers will take these results and build on them. Given that there are thousands of people suffering from Lyme disease and related symptoms<sup>111</sup>, it would be wise to set up a clinical trial using the results of this research to determine the efficacy of chlorine dioxide at a specific concentration on *Borrelia*-related symptoms. The author would welcome such interest from other clinicians.

**Conflict of Interest:** The author has no conflict of interest to declare.

**Acknowledgments:** Gratitude for all the help provided in the laboratory by the microbiologist Annita Poupazi.

Georgiou, GJ. Ph.D.,N.D.,D.Sc (AM),M.Sc.,B.Sc  
Founder Director, Da Vinci BioSciences Research Center, Larnaca, Cyprus.

[info@davinci-labs.eu](mailto:info@davinci-labs.eu) / [admin@docgeorge.com](mailto:admin@docgeorge.com)

## REFERENCES

1. Stricker RB, Johnson L. Lyme disease: the next decade. *Infect Drug Resist.* 2011;**4**:1–9. [PMC free article] [PubMed] [Google Scholar]
2. Stricker RB, Johnson L. Lyme disease diagnosis and treatment: lessons from the AIDS epidemic. *Minerva Med.* 2010;**101**(6):419–425. [PubMed] [Google Scholar]
3. Radolf JD, Caimano MJ, Stevenson B, Hu LT. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. *Nat Rev Microbiol.* 2012. **10**, 87–99.
4. Mead PS. Global epidemiology of *Borrelia burgdorferi* infections. In *Lyme Disease: An Evidence-based Approach*, 2011. pp. 110–114. Edited by J. J. Halperin. Wallingford: CAB International.
5. Kugeler K, Schwartz A, Delorey M, Mead P, Hinckley A. Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018. *Emerg Infect Dis J.* 2021. **27**:616–9. doi: 10.3201/eid2702.202731.
6. Schotthoefer AM, Frost HM. Ecology and epidemiology of Lyme borreliosis. *Clin. Lab. Med.* 2015, **35**, 723–743.
7. Rosenberg R, Lindsey NP, Fischer M, Gregory CJ, Hinckley AF, Mead PS, Paz-Bailey G, Waterman SH, Drexler NA, Kersh GJ et al. Vital signs: Trends in reported vectorborne disease cases - United States and Territories, 2004-2016. *Morb. Mortal. Wkly. Rep.* 2018, **67**, 496–501.
8. Adrion ER, Aucott J, Lemke KW, Weiner JP. Health care costs, utilization and patterns of care following Lyme disease. *PLoS ONE.* 2015. **10**:e0116767. doi: 10.1371/journal.pone.0116767.
9. Adrion ER, Aucott J, Lemke KW, Weiner JP. Health Care Costs, Utilization and Patterns of Care following Lyme Disease. *PLOS ONE.* 2015. **10**(2): e0116767. <https://doi.org/10.1371/journal.pone.0116767>
10. Goodlet KJ, Fairman KA. Adverse events associated with antibiotics and intravenous therapies for post-Lyme disease syndrome in a commercially insured sample. *Clin Infect Dis.* 2018 Oct **30**;67(10):1568-1574.
11. De Wilde M, Speeckaert M, Callens R, Van Biesen W. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of 'chronic Lyme disease'. *Acta Clin Belg.* 2017 Apr;**72**(2):133-137.
12. Klempner MS, Linden MD, Hu T, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall, D, McCall, J, Kosinski, M, Weinstein, A. Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease. *N Engl J Med* Jul 2001; **345**:85-92. DOI: 10.1056/NEJM200107123450202.
13. Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahn S, Dattwyler R, Chandler B. Study and treatment of post Lyme disease (STOP-LD): a randomized double-masked clinical trial. *Neurology.* 2003 Jun **24**;60(12):1923-30. doi: 10.1212/01.wnl.0000071227.23769.9e.
14. Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, Evans J, Weinstein A, Schmid CH, Klempner MS. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? *Neurology.* 2003 Jun **24**;60(12):1916-22. doi: 10.1212/01.wnl.0000068030.26992.25.
15. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology.* 2008 Mar **25**;70(13):992-1003. doi: 10.1212/01.WNL.0000284604.61160.2d. Epub 2007 Oct 10.
16. Mattman LH. *Cell Wall Deficient Forms – Stealth Pathogens*, 3rd edn. 2001. Boca Raton, FL: CRC Press.
17. Berndtson K. Review of evidence or immune evasion and persistent infection in Lyme disease. *Int J Gen Med* **6**, 2013. 291–306.
18. Domingue GJ, Woody, HB. Bacterial persistence and expression of disease. *Clin Microbiol Rev* **10**, 1997. 320–344.
19. Glover WA, Yang Y, Zhang Y. Insights into the molecular basis of L-form formation and survival in *Escherichia coli*. *PLoS ONE* **4**, 2009. e7316.
20. Ranjit DK, Young KD. The Rcs stress response and accessory envelope proteins are required for de novo generation of cell shape in *Escherichia coli*. *J Bacteriol* **195**, 2013. 2452–2462
21. Briers Y, Staubli T, Schmid MC, Wagner M, Schuppler M, Loessner MJ. Intracellular vesicles as reproduction elements in cell wall-deficient L-form bacteria. *PLoS ONE* **7**, 2012. e38514.
22. Flemming HC, Wingender J. The biofilm matrix. *Nat Rev Microbiol* **8**, 2010. 623–633.
23. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, Poruri A, Burugu D, Theophilus PAS, et al. Characterization of biofilm formation by *Borrelia burgdorferi* in vitro. *PLoS ONE* **7**, 2012. e48277.

24. Srivastava SY, de Silva AM. Characterization of *Borrelia burgdorferi* aggregates. *Vector-Borne Zoonotic Dis* 9, 2009. 323–329.
25. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, Poruri A, Burugu D, Theophilus PAS, Pham TV, et al. Characterization of Biofilm Formation by *Borrelia burgdorferi* In Vitro. *PLoS One* 2012, 7, 1–11.
26. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of *Borrelia burgdorferi* and local inflammation in Lyme neuroborreliosis. *J. Neuroinflammation* 2008, 5, 1–18.
27. Meriläinen L, Herranen A, Schwarzbach A, Gilbert L. Morphological and biochemical features of *Borrelia burgdorferi* pleomorphic forms. *Microbiol. (United Kingdom)* 2015, 161, 516–527.
28. Vancová M, Rudenko N, Vaněček J, Golovchenko M, Strnad M, Rego ROM, Tichá L, Grubhoffer L, Nebesářová J. Pleomorphism and viability of the Lyme disease pathogen *Borrelia burgdorferi* exposed to physiological stress conditions: A correlative cryo-fluorescence and cryo-scanning electron microscopy study. *Front. Microbiol.* 2017, 8, 1–9.
29. Brorson O, Brorson S.H. In vitro conversion of *Borrelia burgdorferi* to cystic forms in spinal fluid, and transformation to mobile spirochetes by incubation in BSK-H medium. *Infection* 1998, 26, 144–150.
30. Brorson I, Brorson S.H. An in vitro study of the susceptibility of mobile and cystic forms of *Borrelia burgdorferi* to hydroxychloroquine. *Int. Microbiol.* 2002, 5, 25–31.
31. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in *Borrelia burgdorferi*. *APMIS* 2004, 112, 57–62.
32. Mursic VP, Wanner G, Reinhardt S, Busch U, Maget W. Formation and cultivation of *Borrelia burgdorferi* spheroblast-L-form variants. *Infection* 1996, 24, 218–226.
33. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of *Borrelia burgdorferi* in the Skin. *Am. J. Dermatopathol.* 1996, 18, 571–579.
34. Rudenko N, Golovchenko M, Kybicova K, Vancová M. Metamorphoses of Lyme disease spirochetes: phenomenon of *Borrelia* persists. *Parasit. Vectors* 2019, 12, 1–10.
35. Caccamo PD, Brun YV. The Molecular Basis of Noncanonical Bacterial Morphology. *Trends Microbiol* 2018, 26, 191–208.
36. Justice, SS Hunstad DA, Cegelski L, Hultgren SJ. Morphological plasticity as a bacterial survival strategy. *Nat Rev Microbiol* 2008, 6, 162–168.
37. Domingue GJ, Woody, HB. Bacterial persistence and expression of disease. *Clin. Microbiol. Rev.* 1997, 10, 320–344.
38. Reference for CDSPlus - <https://aquarius-prolife.com>
39. Simpson GD, Miller RF, Laxton GD, Clements WR. A focus on chlorine dioxide: the "ideal" biocide. *Corrosion* 93. *New Orleans, La, March* 1993. 8-12 paper No. 472.. Available: <http://www.clo2.gr/en/pdf/secure/chlorinedioxideidealbiocide.pdf>. Accessed 2013 April 15. [Google Scholar]
40. Nelson TR. "Appleton Papers Finds Chlorine Dioxide to be an Alternative to Conventional Biocides in Alkaline Systems," *TAPPI J.*, 65(6), 69 (1982). 35. T. R. Nelson, "Chlorine Dioxide: An Alternative to Conventional Biocides in Alkaline Systems," paper presented at the Annul. Meet. - Tech. Assoc. Pulp Pap. Ind., 261 (1982). 36. E. R. Balcer, "Using Chlorine Dioxide for Slime Control in Alkaline Paper Machine Systems," *TAPPI J.*, 64(8), 91 (1981). 37. E. R. Baker, "Chlorine Dioxide Proves an Effective Biocide in Alkaline Whitewater Systems," *Pulp Pap.*, 54(8), 140 (1980).
41. MacDonald AB. Spirochetal cyst forms in neurodegenerative disorders,... hiding in plain sight. *Med. Pathogens* 2019, 8, 299 56 of 57 Hypotheses 2006, 67, 819–832.
42. Margulis L, Maniotis A, MacAllister J, Scythes J, Brorson O, Hall J, Krumbein WE, Chanman MJ. Spirochete round bodies syphilis, lyme disease & AIDS: Resurgence of "the great imitator"? *Symbiosis* 2009, 47, 51–58.
43. Synan JF. "Chlorine Dioxide - An Effective Biocide for Recycled or Reused Water Systems," *Trans. Citrus Eng. Conf.*, 1979. 25, 66.
44. Welch JL, Folinazzo JF. "Use of Chlorine Dioxide for Cannery Sanitation and Water Conservation," *Food Tech.*, 1958. March, 179.
45. Sussman S, Ward WJ. "Chlorine Dioxide is an Attractive Treatment Alternative," *W&SW*, 1979. 120.
46. Sussman S, Ward WJ. "Microbiological Control with Chlorine Dioxide Helps Save Energy," *MP*, 1977. 16(7), 24.
47. Ward WJ, Lee JW, Freymark, SG. "Advantages of Chlorine Dioxide as a Biocide," *Ammonia Plant Saf.* 1978.20, 64.
48. Pacheco AM, Durham HE, Dhillon R, Edward C. "The Use of Chlorine Dioxide to Control Microbiological Growth in an Ethylene Glycol Contaminated Cooling Tower... A Case History," *CTI* 1989 Mtg, TP89-14.
49. Sapi E, Kaur, Anyanwu N, Luecke S, Datar, A, et al. Evaluation of in vitro antibiotic susceptibility

- of different morphological forms of *Borrelia burgdorferi*. *Infect Drug Resist* 4:2011. 97–113.
50. [www.attc.org](http://www.attc.org) - [www.lgcstandards.com](http://www.lgcstandards.com)
51. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete *Borrelia burgdorferi* round-body propagules (RBs) by the antibiotic tigecycline. *Proc Natl Acad Sci USA*. 2009. 106:18656–61. 10.1073/pnas.0908236106
52. Barbour AG. Isolation and cultivation of Lyme disease spirochetes. *Yale J. Biol. Med.* 1984. 57:521–525.
53. <https://biotium.com>
54. Feng J, Wang T, Zhang S, Shi W, Zhang Y. An Optimized SYBR GREEN I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for *Borrelia burgdorferi*. *PLoS ONE* 2014. 9(11): e111809.
55. ASTM International. Standard Guide for Assessment of Antimicrobial activity using a time kill procedure. *ASTM Standard*. Designation E2315-16. 2016.
56. <http://www.fluorescencemicroscopy.it/en/diascopy.html>
57. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of *Borrelia burgdorferi*. *Microbiology*. 2000;146:119–27.
58. Zhang Y. Persisters, persistent infections and the Yin-Yang model. *Emerg Microbes Infect.* 2014;3:e3.
59. Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, Pabbati N, et al. Characterization of biofilm formation by *Borrelia burgdorferi* in vitro. *PLoS ONE*. 2012;7:e48277.
60. Kurtti TJ, Munderloh UG, Johnson RC, Ahlstrand GG. Colony formation and morphology in *Borrelia burgdorferi*. *J Clin Microbiol.* 1987;25:2054–8.
61. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of *Borrelia burgdorferi* in the skin. *Am J Dermatopathol.* 1996;18:571–9.
62. Mursic VP, Wanner G, Reinhardt S, Wilske B, Busch U, Marget W. Formation and cultivation of *Borrelia burgdorferi* spheroplast-L-form variants. *Infection*. 1996;24:218–26.
63. Brorson O, Brorson SH. Transformation of cystic forms of *Borrelia burgdorferi* to normal, mobile spirochetes. *Infection*. 1997;25:240–6.
64. Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL. Persisting atypical and cystic forms of *Borrelia burgdorferi* and local inflammation in Lyme borreliosis. *J Neuroinflamm.* 2008;5:40.
65. Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, et al. Evaluation of *in-vitro* antibiotic susceptibility of different morphological forms of *Borrelia burgdorferi*. *Infect Drug Resist.* 2011;4:97–113.
70. Meriläinen L, Herranen A, Schwarzbach A, Gilbert L. Morphological and biochemical features of *Borrelia burgdorferi* pleomorphic form. *Microbiology*. 2015;161:516–27.
71. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in *Borrelia burgdorferi*. *APMIS*. 2004;112:57–62.
72. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrob Agents Chemother.* 1995;39:1127–33.
73. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete *Borrelia burgdorferi* round-body propagules (RBs) by the antibiotic tigecycline. *Proc Natl Acad Sci USA*. 2009;106:18656–61.
74. Drecktrah D, Lybecker M, Popitsch N, Rescheneder P, Hall LS, Samuels DS. The *Borrelia burgdorferi* RelA/SpoT homolog and stringent response regulate survival in the tick vector and global gene expression during starvation. *PLoS Pathog.* 2015;11:e1005160.
75. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of *Borrelia burgdorferi*. *Microbiology*. 2000;146:119–27.
76. Brorson O, Brorson SH. Transformation of cystic forms of *Borrelia burgdorferi* to normal, mobile spirochetes. *Infection*. 1997;25:240–6.
77. Murgia R, Cinco M. Induction of cystic forms by different stress conditions in *Borrelia burgdorferi*. *APMIS*. 2004;112:57–62.
78. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of *Borrelia burgdorferi*. *Antimicrob Agents Chemother.* 1995;39:1127–33.
79. Brorson O, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete *Borrelia burgdorferi* round-body propagules (RBs) by the antibiotic tigecycline. *Proc Natl Acad Sci USA*. 2009;106:18656–61.
80. Caskey JR, Embers ME. Persister development by *Borrelia burgdorferi* populations in vitro. *Antimicrob Agents Chemother.* 2015;59:6288–95.
81. Feng J, Wang T, Shi W, Zhang S, Sullivan D, Auwaerter PG, et al. Identification of novel activity against *Borrelia burgdorferi* persisters using an FDA approved drug library. *EMI*. 2014;3:e49.
82. Gruntar I, Malovrh T, Murgia R, Cinco M. Conversion of *Borrelia garinii* cystic forms to motile spirochetes in vivo. *APMIS*. 2001;109:383–8.
83. Lewis K. Persister cells. *Annu Rev Microbiol.* 2010;64:357–72.
84. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. *Borrelia burgdorferi*, the causative agent of Lyme

- disease, forms drug-tolerant persister cells. *Antimicrob Agents Chemother.* 2015;59:4616–24
85. Hobby GL, Meyer K, Chaffee E. Observations on the mechanism of action of penicillin. *Exp Biol Med.* 1942;50:281–5.
86. Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilization. *Lancet.* 1944;244:497–500.
87. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. *FEMS Microbiol Lett.* 2004;230:13–8
88. Brisson D., Drecktrah D., Eggers CH, Samuels, DS. Genetics of *Borrelia burgdorferi*. *Annu Rev Genet.* 2012; 46: 10.1146/annurev-genet-011112-112140.
89. Ozawa T, Kwan T. Electron spin resonance studies of chlorine dioxide (ClO<sub>2</sub>) in aqueous solutions. *Chem Pharm Bull* 1983; 31: 2864-7.
90. McCarthy JA. Bromide and chlorine as water disinfectants. *J. New Engl Water Works Assoc* 1944; 58: 55-68.
91. Fukuyama MY, Tan H, Wheeler WB, Wei C. Reaction of aqueous chlorine and chlorine dioxide with model food compounds. *Environ Health Perspect* 1986; 69: 267-74.
92. Ogata N, Shibata T. Protective effect of low-concentration chlorine dioxide gas against influenza A virus infection. *J Gen Virol.* 2008. 89: 60-67
93. Morino H, Fukuda T, Miura T, Lee C, Shibata T, Sanekata T. Inactivation of feline calicivirus, a norovirus surrogate, by chlorine dioxide gas. *Biocontrol Sci.* 2009. 14: 147-153.
94. Sanekata T, Fukuda T, Miura T, Morino H, Lee C, Maeda K, Araki K, Otake T, Kawahata T, Shibata T. Evaluation of the antiviral activity of chlorine dioxide and sodium hypochlorite against feline calicivirus, human influenza virus, measles virus, canine distemper virus, human herpesvirus, human adenovirus, canine adenovirus and canine parvovirus. *Biocontrol Sci.* 2010. 15: 45-49.
95. Ma JW, Huang BS, Hsu CW, Peng CW, Cheng ML, Kao JY, Way TD, Yin HC, Wang SS. Efficacy and safety evaluation of a chlorine dioxide solution. *Int J Environ Res Public Health.* 2017. 14: E329.
96. Ofori I, Maddila S, Lin J, Jonnalagadda SB. Chlorine dioxide oxidation of *Escherichia coli* in water - A study of the disinfection kinetics and mechanism. *J Environ Sci Health A Tox Hazard Subst Environ Eng.* 2017. 52: 598-606
97. Simpson GD, Miller RF, Laxton GD, Clements WR (1993) A focus on chlorine dioxide: the "ideal" biocide. *Corrosion* 93. New Orleans, La, March 8-12. paper No. 472.
98. Alvarez ME, O'Brien RT. Mechanism of inactivation of poliovirus by chlorine dioxide and iodine. *Appl Environ Microbiol* 1982; 44: 1064-71.
99. Tachikawa M, Saita K, Tezuka M, Sawamura R. Inactivation of poliovirus with chlorine dioxide. *Jpn J Toxicol Environ Health* 1993; 39: 572-6.
100. Wang XW, Li JS, Jin M, et al. Study on the resistance of severe acute respiratory syndrome-associated coronavirus. *J Virol Methods* 2005; 126: 171-7.
101. Li JW, Xin ZT, Wang XW, Zheng JL, Chao FH. Mechanisms of inactivation of hepatitis A virus in water by chlorine dioxide. *Water Res* 2004; 38, 1514-9.
102. Chen YS, Vaughn JM. Inactivation of human and simian rotaviruses by chlorine dioxide. *Appl Environ Microbiol* 1990; 56: 1363-6.
103. Kawada, Hiroshi, Haneda, Tadayoshi, Soil Disinfection by Using Aqueous Chlorine Dioxide Solutions, Patent application: JP95-111095 13 Apr 1995.
104. Report from Cornell, available from Frontier Pharmaceutical, Inc. upon request.
105. Scatina, J, Abdel-Rahman, M. The Inhibitory Effect of Alcide, an Antimicrobial Drug, on Protein Synthesis in *E. Coli*, *J Appl. Tox.*, 1985, 5, 6.
106. Suh, DH, Abdel-Rahman, MS, Bull, RJ. Effect of Chlorine Dioxide and Its Metabolites in Drinking Water of Fetal Development in Rats, *J. Appl. Toxicol.* 1983, 3, 75-79.
107. Tuthill, RW, Guisti, RA, Moore, GS, Calabrese, FJ. Health Effects Among Newborns After Prenatal Exposure to ClO<sub>2</sub> Disinfected Drinking Water, *Envir. Health Perspect*, 1982, 46, 39-45,
108. Gerges, AR, Skowronski, Effects of Alcide Gel on Fetal Development on Rats and Mice, *J. of Applied Tox.*, 1985, 5, No. 2
109. Haag, HB. The Effects on Rats of Chronic Administration of Sodium Chlorite and Chlorine Dioxide in Drinking Water, Med. Col. Virginia, Dept. Phys, & Pharm., Report to Olin Corp., February 7, 1949
110. Lockett, J., Oxodene: Longevity of Honey Bees, Journal of Econ. Entomology, vol. 65, No. 1, Feb. 1972
111. Tick-Borne Zoonoses in the United States: Persistent and Emerging Threats to Human Health Rebecca J. Eisen, PhD, Kiersten J. Kugeler, PhD, Lars Eisen, PhD, Charles B. Beard, PhD, Christopher D. Paddock, MD. *ILAR J.* 2017 December 15; 58(3): 319–335. doi:10.1093/ilar/ilx005.